Carbonic anhydrase IX: Historical and future perspectives

BJU International, Supplement

Volumn 101, Issue SUPPL.4, 2008, Pages 2-7

  Oosterwijk, Egbert ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; INTERLEUKIN 2; IODINE 124; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY G250; PLACEBO; TRANSCRIPTION FACTOR SP1; VON HIPPEL LINDAU PROTEIN; YTTRIUM 90; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG TARGETING; DRUG UPTAKE; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; LIVER TOXICITY; LUNG METASTASIS; METASTASIS; PH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT RESPONSE; TUMOR BIOPSY; ENZYMOLOGY; METABOLISM;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS;

EID: 44449089520     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 489-494 (Pubitemid 16006918)
2. Pastorek J, Pastorekova S, Callebaut I et al. Cloning and characterization of MN, a human tumour-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994; 9 (10): 2877-2888 (Pubitemid 24296762)
3. Kivela AJ, Parkkila S, Saarnio J et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol 2000; 114: 197-204 (Pubitemid 30764024)
4. Saarnio J, Parkkila S, Parkkila AK et al. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours JHepato/ 2001; 35: 6439
5. Grabmaier K, Vissers JL, De Weijert MC etal. Molecular cloning and immunogenicity of renal cell carcinomaassociated antigen G250. IntJ Cancer 2000; 85: 865-870
6. Oosterwijk E, Bander NH, Divgi CR et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11: 738-750 (Pubitemid 23105683)
7. Divgi CR, Bander NH, Scott AM et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4: 2729-2739
8. Steffens MG, Boerman OC, OosterwijkWakka JC et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 1529-1537
9. Steffens MG, Boerman OC, de Mulder PH etal. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 1311labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5 (10 Suppl.): 3268S-74S
10. Brouwers AH, Mulders PF, de Mulder PH et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131 I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005; 23: 6540-6548
11. 186Re. J Nucl Med 2004; 45: 327-337
12. Uemura H, Nakagawa Y, Yoshida K et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999; 81: 741-746 (Pubitemid 29458875)
13. Gnarra JR, Lerman Ml, Zbar B, Linehan WM. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumourigenesis. Semin Oncol 1995; 22: 3-8
14. Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumourassociated carbonic anhydrases. Cancer Res 2000; 60: 7075-7083
15. Grabmaier K, de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX (G250/MN) by HIF-Ia in clear cell renal cell carcinoma. Oncogene 2004; 23: 5624-5631 (Pubitemid 39093040)
16. Vissers JL, De Vries IJ, Schreurs MW et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999; 59: 5554-5559
17. Vissers JL, De Vries IJ, Engelen LP et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer 2002; 100: 441-444
18. Uemura H.Fujimoto K.Tanaka M et al. A phase I trial ofvaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006; 12: 1768-1775
19. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumour RNA-transfected dendritic cells. Cancer Res 2003; 63: 2127-2133 (Pubitemid 36538616)
20. Greiner J, Schmitt M, Li Letal. Expression of tumour-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117
21. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 200A; 3: 164-167
22. Maseide K, Kandel RA, Bell RS etal. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004; 10: 4464-4471
23. Haapasalo JA, Nordfors KM, Hilvo M etal. Expression of carbonic anhydrase IX in astrocytic tumours predicts poor prognosis. Clin Cancer Res 2006; 12: 473-477
24. Jonathan RA, Wijffels Kl, Peeters W et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 2006; 79: 288-297 (Pubitemid 44093757)
25. Brennan DJ, Jirstrom K, Kronblad A et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 2006; 12: 6421-6431 (Pubitemid 44799714)
26. Yoo H, Baia GS, Smith JS et al. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res 2007; 13: 68-75 (Pubitemid 46121854)
27. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-811 (Pubitemid 36182618)
28. Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004; 171: 2461-2466 (Pubitemid 38625515)
29. Leibovich BC, Sheinin Y, Lohse CM et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007; 25: 475764
30. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11 : 3714-3721 (Pubitemid 40685588)
31. Surfus JE, Hank JA, Oosterwijk E et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibodydependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J lmmunother Emphasis Tumour Immunol 1996; 19: 184-191 (Pubitemid 26234612)
32. Bleumer I, Knuth A, Oosterwijk E et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. BrJCancer2004; 90: 985-990
33. Bleumer I, Oosterwijk E, OosterwijkWakka JC et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175: 57-62 (Pubitemid 41797084)
34. Divgi CR, Pandit-Taskar N, Jungbluth AA et al. Preoperative characterisation of clear-cell renal carcinoma using iodine124-labelled antibody chimeric G250 (124I-CG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8: 304-310 (Pubitemid 46464522)
35. Supuran CT. Carbonic anhydrases as drug targets - an overview. Curr Top Med Chem 2007; 7: 825-833 (Pubitemid 46825080)